Clearside Biomedical reports Q2 EPS (15c), consensus (39c)
Cash and cash equivalents totaled $26.2 million as of June 30, 2019."We continue to make progress in leveraging Clearside's proprietary suprachoroidal space (SCS) injection platform," said George Lasezkay, Pharm.D., J.D., Clearside's Chief Executive Officer. "We recently announced an agreement with Aura Biosciences, which broadens the potential use of our SCS Microinjector(TM) technology into ocular oncology, where there is a significant unmet medical need. With ongoing exposure at medical conferences and in ophthalmic publications highlighting our targeted drug delivery approach, we are exploring various opportunities to prudently build our internal pipeline and we are also attracting significant interest from other companies to partner our technology like we did with Aura Biosciences."